Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyte® imaging system by Lanigan, Thomas M. et al.
www.jbmethods.org 1
POL Scientific
ArticleJournal of Biological Methods  | 2020 | Vol. 7(2) | e133 DOI: 10.14440/jbm.2020.323
Real time visualization of cancer cell death, survival 
and proliferation using fluorochrome-transfected cells 
in an IncuCyte® imaging system
Thomas M. Lanigan, Stephanie M. Rasmussen, Daniel P. Weber, Kalana S. Athukorala, Phillip L. Campbell, David A. Fox, 
Jeffrey H. Ruth*
Division of Rheumatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109
*Corresponding author: Jeffrey H. Ruth, Email: jhruth@med.umich.edu
Competing interests: The authors have declared that no competing interests exist.
Abbreviations used: ATCC, American Type Culture Collection; CMV, cytomegalovirus; DEVD, caspase-3/7 recognition and cleavage sequence; EF1α, elongation factor-1 alpha; 
MOI, multiplicity of infection; NEB, New England Biolabs; NK, natural killer; NLS, nuclear localization signal; PB, peripheral blood; PBMC, peripheral blood mononuclear cell; 
PBS, phosphate-buffered saline
Received November 1, 2019; Revision received April 7, 2020; Accepted April 24, 2020; Published June 12, 2020
ABSTRACT
Cancer immunotherapy is a rapidly advancing and viable approach to treating cancer along with more traditional forms 
of therapy. Real-time cell analysis technologies that examine the dynamic interactions between cancer cells and the 
cells of the immune system are becoming more important for assessment of novel therapeutics. In this report, we use 
the IncuCyte® imaging system to study the killing potential of various immune cells on cancer cell lines. The IncuCyte® 
system tracks living cells, labeled by a red fluorescent protein, and cell death, as indicated by the caspase-3/7 reagent, 
which generates a green fluorescent signal upon activation of apoptotic pathways. Despite the power of this approach, 
obtaining commercially fluorescent cancer cell lines is expensive and limited in the range of cell lines that are available. 
To overcome this barrier, we developed an inexpensive method using a lentiviral construct expressing nuclear localized 
mKate2 red fluorescent protein to stably label cancer cells. We demonstrate that this method is effective in labeling a wide 
variety of cell lines, allowing for analyses of different cancers as well as different cell lines of the same type of cancer.
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INTRODUCTION
The relationship between cancer and the immune system has been 
intensely studied for decades [1]. To use the intrinsic ability of the hu-
man immune system to recognize and eliminate tumors is an appealing 
therapeutic strategy [2,3]. However, cancer cells employ a number of 
immunosuppressant mechanisms that result in an ineffective immune 
response [4,5]. Multiple approaches in cancer immunotherapy (such 
as monoclonal antibodies, cancer vaccines and immune checkpoint 
therapy) are rapidly advancing the field, but challenges still exist in 
making these therapies effective [1,3,6].
The interaction between cancer cells and immune effector cells is 
complex and incompletely understood. Live-cell imaging technologies 
allow for visualization, characterization and measurement of biological 
processes in living cells. These technologies will play an important 
role in the development and validation of the next-generation of can-
cer immunotherapies. Simple live-cell imaging assays from target cell 
apoptosis, cytotoxic cell polarization and cell migration assays to more 
complex co-culture systems, such as immune cell killing and phagocy-
tosis assays, will be critical for the characterization of these functions 
and development of new therapeutics.
In the past 20 years, development of novel fluorescent tools to 
measure apoptosis by live-cell imaging technologies has facilitated the 
study of these cell processes and cell interactions [7]. These include 
the fluorogenic caspase substrates Phi-PhiLux and NucView488, which 
are non-toxic, cell-permeable reagents designed to track caspase acti-
vation in living cells [8-10]. These substrates consist of dyes that are 
linked to a caspase-3/7 recognition and cleavage sequence (DEVD) 
[11,12]. The substrates are not fluorescent until cleaved by caspase [7]. 
These fluorescent tools enable real-time detection and quantification 
of intracellular caspase-3/7 activity over hundreds of time points due 
to immunotherapy manipulation using live-cell imaging technologies. 
This technology offers a significant advantage over the other existing 
methods such as in situ nick-end labeling (TUNEL) assay, mitochondrial 
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membrane potential assay, and annexin V and propidium iodide combi-
nation staining. These assays are limited in the number of time points 
that can be assayed, are time consuming to run, can require significant 
optimization to get reproducible data and often need to be coupled with 
a second assay to confirm a positive apoptotic result.
To further understand cancer cell-immune response dynamics, we 
fluorescently labeled multiple cancer cell lines to better visualize the 
immune cell interaction with cancer cells. The cancer cells were stably 
labeled using a lentivirus expressing nuclear localized mKate2 fluores-
cent protein (red). The lentiviral approach enables the establishment of 
stably fluorescent cancer cell lines in a rapid and cost-efficient manner. 
In these experiments, mKate2 (red) cancer cell lines were treated with 
IncuCyte® caspase-3/7 apoptosis reagent, a version of NucView488 
(green), to measure apoptosis induced by immunotherapy treatments 
as visualized on the IncuCyte® Imager (Sartorius, USA). In this paper, 
we describe the methodology for generating fluorescent-labeled cancer 
cell lines for live-cell analysis on an IncuCyte® Imager.
MATERIALS AND METHODS
Lentiviral construction
Generation of the mKate 2X nuclear localization signal (NLS) 
lentiviral expression vector was done as follows. mKate cDNA was 
amplified from pmKate2-C vector (Evrogen) using the following prim-
ers: mKate F SphI 5’-AAT GCA TGC GCC ACC ATG GTG AGC 
GAG CTG ATT AAG GAG -3’; mKate 2X NLS R BamHI 5’- TAG 
AGG ATC CTT ACT TCT ACC TTT CTC TTC TTT TTT GGA TCT 
ACC TTT CTC TTC TTT TTT GGA TCA GCT CGA GAT CTT CCT 
CTG TGC CCC AGT TTG CTA GGG AGG -3’. The NLS sequence 
is underlined in the mKate 2X NLS primer above. PCR amplification 
of mKate 2X NLS was done using Phusion Taq Polymerase with the 
5X GC Buffer (NEB) following the manufacturer’s instruction using 
touchdown PCR cycling conditions [13]. The cycling conditions were 
as follows: 98°C 30 s 1 cycle; 98°C 15 s, 67°C (−0.5°C/cycle), 72°C 
30 s 12 cycles; 98°C 15 s, 61°C, 72°C 30 s 61 cycles. The resulting 
mKate 2X NLS PCR product was isolated using the Monarch DNA 
Gel Extraction Kit (NEB), digested with SphI and BamHI, and ligated 
using the same sites in pLentiLox EF1α-CMV-Puro lentiviral transfer 
vector (available from University of Michigan Vector Core) generating 
pLentilox EF1α-mKate 2X NLS-Puro. The vector was verified by Sanger 
sequencing. See Fig. S1 for the full plasmid map, sequence, and primer 
design for pLentilox EF1α-mKate 2X NLS-Puro.
Lentiviral production
For lentivirus production, the packaging vectors psPAX2 (35 μg), 
pC1-VSVG (35 μg) and 70 μg of pLentilox EF1α-mKate 2X NLS-Puro 
transfer plasmid were incubated with 420 μg PEI (molecular weight 
2500, Polysciences, Inc) in 10 ml of Optimem (Life Technologies) at 
room temperature for 20 min. Ninety milliliters of complete DMEM 
[(Gibco, Cat. #11965; 10% FBS (Hyclone) and 1× GlutaMAX (Gibco)] 
was added to the transfection mix and was distributed equally between 
5-T150 flasks (Falcon) of 80% confluent HEK293T cells. Supernatants 
were collected and pooled after 72 h, filtered with a 0.45 micron HV-Du-
rapore Stericup (Millipore), pelleted by centrifugation at 13000 rpms 
on a Beckman Avanti J-E centrifuge at 4°C for 4 h, and re-suspended 
at 10× the original concentration (~1 × 107 TU/ml) in DMEM (Gibco). 
The lentivirus was stored in aliquots at −80°C.
Lentiviral transduction and cell isolation
One day prior to lentiviral transduction, cancer cells were seeded 
at 3.0 × 105 cells/well on 6 well plates (Corning) in media containing 
RPMI 1640 (HyClone), 10% FBS (HyClone), and 1% antibiotic-anti-
mycotic solution (Gibco). Cell media was changed to 1.35 ml of fresh 
antibiotic-free RPMI 1640 with 10% FBS supplemented with 150 µl 
of 10× virus (~6 MOI) and 4 µg/ml Polybrene (Sigma-Aldrich). The 
cells were incubated at 37°C with 5% CO2 for 24 h. Following incu-
bation, cells were trypsinized (0.25%-EDTA, HyClone), collected, 
and centrifuged at 600 RCF for 6 min at 4°C in an Eppendorf 5702 
R centrifuge. The cells were plated in RPMI 1640 with 10% FBS and 
1% antibiotic-antimycotic solution on a T75 flask (Corning) and grown 
until confluent. Cells were trypsinized, collected and centrifuged as 
done previously. Following centrifugation, cells were re-suspended in 
1× PBS (HyClone) and counted with a hemocytometer using Trypan 
blue (Life Technologies) exclusion. Cells were then centrifuged and 
re-suspended in Zombie Violet (BioLegend) diluted in 1× PBS (1:4000) 
at a concentration of ~1 × 106 cells/ml and incubated on ice, in the dark, 
for 20 min. Cells were washed once with 1× PBS and then re-suspend-
ed at a final concentration of ~2 × 106 cells/ml in 2% FBS and 2 mM 
EDTA (Invitrogen). The cells were then singly sorted into individual 
wells of a 96 well plate (Corning) containing RPMI 1640, 10% FBS, 
and 1% antibiotic-anti-mycotic solution at the University of Michigan 
Flow Cytometry Core using a Synergy Head Cell Sorter (Sony). The 
cells selected were negative for Zombie Violet [450/50 (405)] and in 
the top 5% of mKate fluorescence intensity [615/30 (561)]. The sorted 
cells were then incubated at 37°C with 5% CO2 and monitored on the 
IncuCyte® Live Cell Analysis System (Sartorius, USA). Cell isolates 
with strong fluorescence and growth were selected for expansion.
Immune/cancer cell co-culture experiments
Peripheral blood mononuclear cells (PBMCs) used in co-culture ex-
periments were activated, plated and grown similarly as described below 
unless stated otherwise. MDA 231 human breast cancer cells (HBCCs) 
were plated in a 96-well plate with a seeding density of 20000 cells per 
well. Non-activated (NA) or OKT3 activated PBMCs (50000 cells per 
well) were added to the MDA 231 cells (n = 3 wells for each cell line) 
at about 22 h. Cell killing was measured by evaluating the number of 
MDA 231 cells present in each well expressing caspase-3/7 reagent and 
results pooled. Co-culture conditions, including cell numbers and OKT3 
activation of PBMCs were modified from Essen Instruments protocol 
“IncuCyte® Immune Cell Killing, Clustering & Proliferation Assay” which 
can be obtained online (https://www.essenbioscience.com/media/uploads/
files/Immune_Cell_Killing-Clustering-Proliferation_Assays_brochure.
pdf). Briefly, for OKT3 activated PBMCs, 1 × 106 cells were incubated 
with 10 µg/ml OKT3 antibody overnight. Activated PBMCs were then 
counted and added to the co-culture as described above.
Isolation of human PB and lymphocytes
Peripheral blood (PB) from normal adult donors was collected in 
heparinized tubes. After centrifugation, the buffy coat was collected and 
mononuclear cells were purified under sterile conditions on an Accu-Prep 
gradient at 400× g for 30 min at room temperature. Mononuclear cells 
collected at the interface were washed twice with PBS and re-suspended 
in purified PBS (Life Technologies—Bethesda, MD). Mononuclear cell 
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viability was typically 98% as determined by trypan blue exclusion. 
Lymphocyte separation is performed using EasySep™ Human Cell 
Isolation Kits per the manufacturer’s protocol (STEMCELL Technol-
ogies—Vancouver, BC). To prevent unwanted lymphocyte activation, 
lymphocyte subsets are isolated using a column-free magnetic negative 
isolation system that provided a reliable source of specific lymphocyte 
subsets for use in our assays. Some cells were fluorescently tagged for 
use in our cell imager. Cytospin examinations were performed upon all 
isolations to ensure purity of the cells used in our assays, and subset purity 
was routinely confirmed by FACS and/or cytospin differential analysis.
Statistics
All data is expressed as the mean ± standard error of the mean (SEM). 
All in vitro assays were evaluated with an unpaired, parametric Student’s 
t test for each time point measured in the IncuCyte® cell imaging system. 
Two-tailed P-values < 0.05 were considered statistically significant.
RESULTS
Utilizing the IncuCyte® live-cell analysis system to 
quantify immune cell killing responses of cancer cell 
lines in real-time
We used the Sartorius IncuCyte® system to examine the dynamics of 
immune cell killing of cancer cell lines in culture. Using this system, we 
cultured nuclear localized red fluorescent-labeled MDA 231 breast cancer 
cells, obtained from Sartorius, in the presence of IncuCyte® caspase-3/7 
reagent (Sartorius, USA) (Fig. 1A). The Sartorius Caspase-3/7 reagent, 
similar to NucView488 [8], is a cell-permeable, non-toxic dye conju-
gated to the caspase-3/7 recognition and cleavage sequence (DEVD) 
[12]. It is non-fluorescent until activated by caspase-3/7 apoptosis 
activity. Once cleaved, the dye is capable of fluorescing green upon 
DNA binding, thus identifying the dead and dying cells. As a proof of 
principle that this system works as expected, we treated the cells with 
a known apoptosis inducing drug, staurosporine (Fig. S2). We find that 
the number of red fluorescent MDA 231 cells increase in number until 
shortly after the addition of staurosporine whereupon the number of 
red MDA 231 cells then begin to decrease, and the number of green 
apoptotic cells increase. These experiments serve as a positive control 
for the co-culture experiments in which the green cells indicate cell 
death due to apoptosis. Our data using staurospoine also shows that 
1.2 µM staurosporine kills MDA 231 breast cancer cells more effec-
tively than the lower dose of 0.6 µM staurosporine, demonstrating that 
elevated concentrations of staurosporine are more effective at killing 
tumor cells in vitro.
Using this system, we added activated or non-activated PBMC cells 
(non-fluorescent) to the Sartorius MDA 231 cells (red fluorescent and 
treated with caspase-3/7 reagent). Non-activated PBMCs can induce 
cell death but at much lower level than activated PBMCs generated 
using OKT3 stimulation (Fig. 1).
Figure 1. The IncuCyte® live-cell analysis system to study immune cell kill responses of cancer cell lines in real-time. A. Schematic representation 
of the duel color monitoring system to track live cells by fluorescent protein expression (red) and cell death or apoptosis (green) by caspase-3/7 reagent. 
B. Red fluorescent MDA 231 cells (Sartorius) co-cultured with non-activated control or OKT3 activated PBMCs are imaged using the IncuCyte® system. 
Images are taken 60 h post co-culture with PBMCs or scan No. 120 (see C). C. Real-time viability measurements are shown. Non-activated (NA) PBMC 
control conditions are shown in green circles and OKT3 activated PBMCs shown by red circles. The graph on the left compares the live (red) cells and 
the graph on the right compares the green (dead) cells between NA and activated PBMCs. 20000 red fluorescent MDA 231 cells and 50000 non-activated 
control or OKT3 activated PBMCs were cultured. Statistical analysis was performed between NA and activated PBMCs for both cell survival and cell 
death with P-values indicated on the graph. The graph (left) showing live cells has a P < 0.05 for every time point from scan 69–140. The graph (right) 
for cell death has a P < 0.05 for time points between scan 40–90 and 100–140. Data is the mean of 3 independent wells per time point ± SEM. Images 
were taken at 10× magnification on the IncuCyte® imager.
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At 60 h post co-culture, there was a significant increase in cancer 
cell death in the presence of activated PBMCs (Fig. 1B, right panel) 
compared to a reduction in tumor cell death in the presence of the control 
non-activated PBMCs (Fig. 1B, left panel). Cell death is indicated by 
widespread cell clumping of green-fluorescing cells that have cleaved 
the caspase-3/7 reporter reagent (Fig. 1B, right panel). The rate and 
degree of cell death was measured in real-time using the IncuCyte® 
imaging system (Fig. 1C). At approximately 35 h post treatment (scan 
No. 70), the number of live red cells (Fig. 1C, left graph) began to 
decrease in the presence of activated PBMCs, whereas the number of 
live red cells treated with the non-activated PBMC control continued 
to increase until plateauing at 45 h post treatment. In measuring the 
green apoptotic cells (Fig. 1C, right graph), the number of green cells 
significantly increased in the presence of activated PBMCs at 45 h post, 
whereas the number of green cells treated with non-activated PBMCs 
remained relatively unchanged. Statistical analysis was performed for 
both cell survival and cell death measurements between cells co-cultured 
with non-activated and activated PBMCs with P-values indicated on the 
graphs in Figure 1C. The graph (left) showing live cells has a P < 0.05 
for every time point from scan 69–140. The graph (right) for cell death 
has a P < 0.05 for time points between scan 40–90 and 100–140. These 
results demonstrate the power of the IncuCyte® system in measuring 
the immune cell-cancer cell killing dynamics.
To test the limits of the co-culture experiments, red fluorescent-labeled 
MDA 231 were plated at the following MDA/non-activated PBMC cell 
number ratios: 50000/50000, 50000/20000, 20000/100000, 20000/50000, 
and 10000/100000 (Fig. S3). As shown, the ratio of 20000/50000 is 
suitable for testing potential therapeutics since this tumor cell/PBMC ratio 
does not severely affect tumor cell survival and does not overly induce 
apoptosis. Therefore, this ratio was used throughout the manuscript.
Generation of stably-labeled red fluorescent cells using 
a nuclear localized mKate2 expressing lentivirus
To effectively perform tumor cell killing assays with co-cultured 
immune cells, clear visualization of the cancer cells as well as the 
effector immune cells is required. Although stably fluorescent cancer 
cell lines are commercially available for some tumor cell lines, they 
are expensive and cost prohibitive for many researchers—especially 
if one desires to study several different cancer cell lines or tumor cells 
from rare or commercially unavailable tumor biopsies. Thus, we gen-
erated our own nuclear localized fluorescently labeled cell lines using 
lentivirus to stably express the red fluorescent mKate2 protein (Fig. 2).
Figure 2. Generation of stably-labeled red fluorescent cells using a nuclear localized mKate2 expressing lentivirus. A. Layout of the pLentilox 
EF1α-mKate 2X NLS-Puro construct. The construct expresses mKate2 fused to two nuclear localization sequences expressed by the EF1α promoter. A 
second expression cassette of CMV promoter driving the puromycin selectable marker is included. B. Schematic representation of experimental design 
of generating fluorescently label cancer cell lines. Cells were transduced with lentivirus expressing mKate2, grown to confluence and the strongest 
expressing cells isolated for expansion. Shown is a FACS diagram sorting the top 5% of fluorescing A375 cells and corresponding image of cells after 
clonal isolation. C. Image of ATCC MDA 231 cells, transduced with lenti-mKate2 and clonally isolated compared to non-transduced control. Images were 
taken at 10× magnification on the IncuCyte® imager.
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To generate the lentiviral construct, we inserted the mKate2 fluo-
rescent gene tagged with two C-terminal nuclear localization signals 
behind the constitutively active EF1α promoter. The EF1α promoter 
was chosen due to its consistently strong expression across a wide range 
of cell types and resistance to being silenced over time by epigenetic 
factors such as DNA methylation [14,15]. This construct also contains 
a CMV promoter driven-puromycin resistance selectable marker cas-
sette (Fig. 2A). The construct was then packaged into lentivirus and 
used to transduce cancer cells obtained from American Type Culture 
Collection (ATCC, USA). For cloning, transduced tumor cells were 
passaged and grown to confluence, then sorted by flow cytometry and 
clonally plated onto 96 well plates (Fig. 2B). Notably, only the top 5% 
of cells expressing the highest fluorescence intensity were selected for 
single cell cloning. Clonal isolates were further monitored for growth 
using the IncuCyte® imaging system. The brightest, best-growing clones 
were selected for further expansion and analysis. The first cancer cell 
line generated using this system was MDA 231 cells obtained from 
ATCC. As shown in Figure 2C, these MDA 231 breast cancer cell lines 
fluoresce as strongly as the MDA 231 cell line obtained commercially 
(see Fig. 1C).
Generation of multiple cancer cell lines transduced 
with lentivirus mKate2
An effective cell labeling method must consistently work on a diverse 
set of human cancer cell lines. Multiple lines from ATCC (Table S1) 
were chosen not only from the same cancer type—but across different 
cancer cell lines to test for consistency and to test the range of effective 
cell labeling (Fig. 3). We used lenti-mKate2 to label five breast cancer 
cell lines: MDA 231 cells (Fig. 2C), MDA 436 cells (Fig. 3A), T47D 
cells (Fig. 3B), MCF-7 cells (Fig. S4), and BT-474 (Fig. S4); three 
melanoma lines: A375 cells (Fig. 3C), A375 MA2 cells (Fig. S4), and 
Mel-1 cells (Fig. S4); one prostate cancer line: (LNCAP cells (Fig. 3D); 
and two lung cancer lines: A549 cells (Fig. S4) and NCI-H460 cells (Fig. 
S4). All transfected tumor cell lines were clearly labeled with the red 
fluorescent mKate2 marker despite different origins, morphologies, and 
growth rates. Lenti-mKate2 labeled cells were treated with caspase-3/7 
reagent and little to no level of background green fluorescence can be 
detected (Fig. 3).
Figure 3. Generation of multiple cancer cell lines transduced with lentivirus mKate2 and clonally isolated. A. MDA 436 breast cancer cells, B. 
T47D breast cancer cells, C. A375 melanoma cells and D. LNCAP prostate cancer cells were stably labeled with lenti-mKate2. These cells were ana-
lyzed on the IncuCyte® system for up to 6 d in the presence of caspase-3/7 reagent. Images are taken at the 60 h time-point at 10× magnification on 
the IncuCyte® imager.
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Functional testing of lenti-mKate2 transduced cancer 
cell lines in real-time cell viability assays
To functionally assess interactions between lenti-mKate2 labeled 
cancer cell lines and human immune cells, several cell lines were tested 
under varying conditions (Fig. 4). First, 20000 MDA 436 breast cancer 
cells treated with the caspase-3/7 reagent were cultured with (Fig. 4A) 
or without (Fig. 3A) 50000 non-activated CD3+ T cells. Cells were 
analyzed in real-time by the IncuCyte® imaging system and images are 
shown at 60 h after treatment with CD3+ T cells. There is significantly 
more cell death in the presence of CD3+ T cells as compared to control 
wells (Fig. 3A, and Fig. 4A, left graph). Concomitantly, there is a 
modest increase in live cell number of MDA 436 cells with caspase 
reagent only (Fig. 3A) compared to cells co-cultured with CD3+ T cells 
(Fig. 4A, right graph). Statistical analysis shows a P < 0.05 for every 
time point between scan 20–325 for cell death (left graph) and between 
scan 70–324 for live cells.
Figure 4. Functional testing of lenti-mKate2 transduced cancer cell lines in real-time cell viability assays. Red fluorescent cancer cell lines are 
co-cultured with immune cells and analyzed using the IncuCyte® system. Breast cancer cells lines MDA 436 (A) and T47D (B) were co-cultured with 
non-activated CD3
+
 T cells or caspase reagent only as control (compare 4A with 3A and 4B with 3B, respectively). C. A375 melanoma cells were co-cul-
tured with either natural killer (NK) cells or non-activated PBMCs as a positive control. All cells were treated with caspase-3/7 reagent prior to co-culture. 
Images are taken at the 60 h time point. Real-time viability measurements are shown in the graphs. The graphs on the left compared the dead (green) 
cells and the graphs on the right compared the red (live) cells between culture conditions. In each experiment, 20000 cancer cells were co-cultured with 
50000 T-cells, NK cells or PBMC cells. Results are representative of three biological replicates. Statistical analysis was performed and P-values are 
indicated on each graph. Each time point (scan) between the arrows indicates a P < 0.05. Data is the mean of 3 independent wells per time point ± SEM. 
Images were taken at 10× magnification on the IncuCyte® imager.
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A comparable experiment was performed using T47D breast cancer 
cells resulting in a similar outcome. The growth/death rates were again 
measured in real-time on the IncuCyte® imager (Fig. 4B). As shown, 20000 
T47D cells treated with 50000 CD3+ T cells had more cell death and fewer 
live cells compared to caspase reagent only control wells (compare Fig. 
3B to Fig. 4B, Fig. 4B left and right graph, respectively). A P < 0.05 was 
determined for all time points between scan 100–324 for cell death (left 
graph) and scan 85–324 for live cells (right graph). Finally, we compared 
the killing potential of 50000 PBMCs and isolated natural killer cells (NK) 
on 20000 A375 melanoma cancer cells (Fig. 4C). A375 cells were treated 
with caspase-3/7 reagent and then co-cultured with either non-activated 
PBMCs as a positive control or NK cells. Tumor cells were monitored 
in real-time on an IncuCyte® imaging system for 94 h. Analysis of the 
green cells shows a significant increase in cell death when co-cultured 
with PBMCs, as expected, but not significant cell death with NK cells 
(Fig. 4C, left graph) (P < 0.05 from scan 25–188) in which A375 cells 
(red) continued to grow in the presence of NK cells. By contrast, A375 cell 
numbers plateaued sooner in the presence of the PBMC positive control 
than with NK cells (Fig. 4C, right graph) (P < 0.05 from scan 75–188). 
Images of A375 cells at 60 h post co-culture shows the majority of cells 
have turned green when treated with PBMCs, but remain mostly red 
when treated with NK cells. Overall, these experiments demonstrate 
that interactions between the lenti-mKate2 labeled cells and immune 
cells can be readily visualized and quantitated in real-time.
DISCUSSION
Live-cell imaging analysis allows for the study of cellular dynamics 
in real time. These powerful techniques depend on live tracking of target 
and effector cells. Parameters such as cell growth, death, migration and 
intracellular and extracellular trafficking can be measured in real time 
instead of static snapshots of single time points. The standard approach 
is to use stably transfected fluorescently labeled cells, usually with high 
intensity. This relatively simple component can be the limiting factor to 
utilizing the full potential of live-cell imaging of fluorescently labeled 
cancer cells. Although, these cells are commercially available, purchasing 
such cells can be very expensive and therefore cost prohibitive, espe-
cially for investigations that are designed to test a single therapeutic 
on a wide variety of tumor cells. Secondly, the number and type of 
commercially available cancer cell lines appropriately labeled for use 
in a cell imaging system are very limited. Thirdly, available cancer cell 
lines may have different and/or unwanted genetic backgrounds (e.g., p53 
mutation vs. Ras mutation) [16,17] that may or may not be relevant, or 
unnecessarily interfere with experimental interpretation and/or results. 
These factors were paramount when designing the pLentilox EF1α-
mKate 2X NLS-Puro construct. The mKate2 fluorescent marker was 
specifically used for its high intensity fluorescence required for quality 
live-cell imaging. The nuclear localization of mKate2 is essential for 
distinct cells to be clearly delineated for superior masking of cells in the 
live-imaging experiments. Cell masking is process where the imager is 
programed to measure just the cells of interest, blocking out all other 
cells and debris. This process is essential for obtaining accurate data. 
In addition, it is common for stably derived cell lines to epigenetically 
silence expression over time by DNA methylation of the promoter. To 
minimize the chance of this occurring, we used the housekeeping gene 
promoter, EF1α, which is more resistant to silencing than strong consti-
tutively active viral promoters, which are commonly used in lentiviral 
constructs. These characteristics of the pLentilox EF1α-mKate 2X 
NLS-Puro create fluorescently-labeled cells that are superior to other 
lentiviral-generated fluorescently-labeled cells for live-cell imaging 
that we examined in the IncuCyte®.
To maximize the benefits of the pLentilox EF1α-mKate 2X NLS-Puro 
construct, our methods were designed to isolate the highest expressing 
clones that optimize the cellular fluorescence of the resultant tumor cells. 
Our transduced cells are comparable in fluorescence to those obtained 
commercially, and functioned similarly when tested in co-culture using 
an IncuCyte® cell imaging system. The ten cell lines we transduced 
with lenti-mKate2 were clonally isolated fairly easily using standard 
cell culturing techniques and reagents. For tumor cells that cannot 
grow from a single cell clone, this method should work by cell sorting 
the top 5% of fluorescent cells and growing them as a heterogeneous 
population. From these studies, we were able to show that this method 
is a high quality, high efficiency and low cost approach for generating 
fluorescent cells from multiple types of cancers.
Recent studies investigating the interactions of cytotoxic T lympho-
cytes with melanoma tumor cells [18] and a cell-engineered system 
to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity 
[19] were done using the standard methodology. Neubert et al. used 
flow cytometry to measure living cells and chromium release assay to 
evaluate cell killing. These data were limited by the number of time 
points (3 or 4) for each experiment. The error bars for some points are 
substantial, although not unusual for these types of studies. Further-
more, the chromium release assay used radioactive chromium (51Cr) 
in the experiment. Similar experimental limitations were observed in 
Nelson et al., which used FITC annexin V for apoptosis detection to 
measure apoptotic cell death. These older methods may be limited by 
the number of time points, the reproducibility of results, and in some 
cases, the dependence on radioactivity. Use of live-cell imaging re-
duces or eliminates these disadvantages. Hundreds of time points can 
be measured, across several replicates with great reproducibility as 
indicated by the small error bars at each time point. Data is captured 
and processed by the IncuCyte®, eliminating time consuming assays, 
and radioactivity is not required.
The search for immuno-therapies against cancer is an active area of 
research [2,3]. In order to maximize the effectiveness of these targeting 
strategies, a robust system for labeling cancer cells in a rapid and cost 
effective manner is essential. Live-cell imaging technologies that can 
visualize, characterize and quantitate interactions between immune cells 
and tumor cells may identify the most effective therapeutic regimens for 
treating cancer. These fluorescent labeling systems can also be used to 
evaluate the efficacy of antibody based therapies for cancers that do not 
respond to traditional treatments. They can also contribute as a valuable 
drug development tool for identifying and improving our understanding 
of the binding interactions between lymphocytes and tumor cells (i.e., 
receptor-ligand interactions). Moreover, the potential of these labeling 
systems can also lend themselves to testing other relevant therapies apart 
from immune based therapeutic approaches for cancer.
Lastly, translational applications for customized medicine using these 
approaches may help identify when resistance occurs in patients—and 
aid in the development of novel, multi-tiered approaches for treatment 
of several cancers. This system can also be used to understand how 
therapies affect neighboring non-cancer cells in comparison to cancer 
cells in real time. A two color assay system for concurrently measuring 
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living cells, and cell death, can provide a greater degree of confidence 
in the cellular dynamics under different co-culture conditions. As live-
cell technologies advance, the addition of multiple fluorescent reporters 
would add depth to understanding concomitant processes in the search 
for more effective cancer therapies, as well as advance our understanding 
of critical biological pathways in tumor cells.
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